City
Epaper

AstraZeneca recalls Covid vax: Risk-benefit currently against further use, say experts

By IANS | Updated: May 8, 2024 17:15 IST

New Delhi, May 8 The risk-benefit of AstraZeneca's Covid-19 vaccine is currently against further use, said experts on ...

Open in App

New Delhi, May 8 The risk-benefit of AstraZeneca's Covid-19 vaccine is currently against further use, said experts on Wednesday amid a report of a global recall of the jab by the British-Swedish pharma giant.

The recall of its Covid-19 vaccine, made in collaboration with Oxford University, worldwide, comes after the drugmaker in February admitted in the UK court about its potential side effect -- Thrombotic Thrombocytopenic Syndrome (TTS), a rare blood clot disorder.

The Telegraph reported AstraZeneca voluntarily withdrew "marketing authorisation" of its Covid vaccine, sold as Covishield in India and Vaxzevria in Europe.

While it can now no longer be used in the European Union, the company said it will initiate withdrawals from the global market.

"It is no longer a useful vaccine. The virus has changed. The risk-benefit currently is against further use," Anurag Agrawal, Dean, Trivedi School of Biosciences, at Ashoka University, told IANS.

"In India, with severe Covid becoming less common presently, possibly due to a combination of hybrid and herd immunity, a decision to vaccinate with the AstraZeneca vaccine should be made after discussing the likely risks and benefits. This is especially true for younger and low-risk individuals," added Lancelot Pinto, Consultant Pulmonologist and Epidemiologist, P. D. Hinduja Hospital and MRC, Mumbai.

The company, credited for saving more than six million lives during the recent Covid-19 pandemic, "accepted, in a legal document submitted to the High Court in February, that its Covid vaccine 'can, in very rare cases, cause TTS'," the report said.

TTS is a rare side effect that can cause people to have blood clots and a low blood platelet count and has been linked to at least 81 deaths in the UK as well as hundreds of serious injuries.

Lancelot told IANS that TTS occurs "possibly due to the adenovirus vector".

"A systematic review including studies conducted till August 2021 found 167 reported cases worldwide. The incidence is believed to be 2 per 100,000 people vaccinated with AstraZeneca aged 60 years or older, 2-3 per 100,000 people vaccinated with AstraZeneca aged under 60 years" he added.

Importantly, the doctor noted that "the side effects typically appear within 6 weeks post-vaccination, and are more common after the first dose".

As per modelling estimates, Covid vaccination saved between 14.4-19.8 million deaths in the first year, reducing deaths by 63 per cent.

Meanwhile, AstraZeneca in a statement said that the vaccine recall is due to "commercial reasons". It said that with multiple Covid variants and related vaccines, "there is a surplus of available updated vaccines".

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other SportsWomen’s ODI tri-series: Bowling is something we need to work on, says Harmanpreet

InternationalNepal's National Assembly Chairperson draws govt's attention to thoroughly investigate death of 2 students in Odisha's KIIT

CricketAndre Russell completes 1000 IPL runs; joins Gambhir, Uthappa in record books

NationalMP, Chhattisgarh continue to experience turbulent weather; rain, thunderstorm, lightning in several districts

TechnologyScientists create hair-like electrode to monitor brain’s electrical activity

Health Realted Stories

HealthScientists create hair-like electrode to monitor brain’s electrical activity

HealthSC to hear on Monday plea against two shifts in NEET PG 2025

HealthAngolan President seeks closer ties with India in pharma, agriculture, renewable energy

HealthHand hygiene is not a luxury, it is the cornerstone of safe healthcare: Saima Wazed

HealthSouth Korea reports 52 cases of measles, highest in 6 years